American Journal of Kidney Diseases
Volume 53, Issue 3 , Pages 457-466 , March 2009

The ABCs of Cardioprotection in Dialysis Patients: A Systematic Review

  • James B. Wetmore, MD

      Affiliations

    • Department of Medicine, Division of Nephrology and Hypertension, University of Kansas School of Medicine, Kansas City, KS
    • Corresponding Author InformationAddress correspondence to James B. Wetmore, MD, Department of Medicine, Division of Nephrology and Hypertension, University of Kansas School of Medicine, MS 3002, 3901 Rainbow Blvd, Kansas City, KS 66160
    • ,
  • Theresa I. Shireman, PhD, RPh

      Affiliations

    • Department of Preventive Medicine and Public Health, University of Kansas School of Medicine, Kansas City, KS

Received 30 January 2008 ,Accepted 30 July 2008.

References 

  1. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement (Quality of Reporting of Meta-analyses). Lancet. 1999;354:1896–1900
  2. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting (Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group). JAMA. 2000;283:2008–2012
  3. Egger MAD. Systemic reviews of observational studies. In:  Egger MAD editors. Systemic Reviews in Health Care: Meta-Analysis in Context. (ed 2). London, UK: BMJ; 2001;p. 211–227
  4. Trespalacios FC, Taylor AJ, Agodoa LY, et al. Incident acute coronary syndromes in chronic dialysis patients in the United States. Kidney Int. 2002;62:1799–1805
  5. Foley RN, Herzog CA, Collins AJ. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int. 2002;62:1784–1790
  6. Kestenbaum B, Gillen DL, Sherrard DJ, et al. Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int. 2002;61:2157–2164
  7. Trespalacios FC, Taylor AJ, Agodoa LY, et al. Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis. 2003;41:1267–1277
  8. Griffith TF, Chua BS, Allen AS, et al. Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 2003;42:1260–1269
  9. Abbott KC, Trespalacios FC, Agodoa LY, et al. Beta-blocker use in long-term dialysis patients: Association with hospitalized heart failure and mortality. Arch Intern Med. 2004;164:2465–2471
  10. Ishani A, Herzog CA, Collins AJ, et al. Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect?. Kidney Int. 2004;65:1017–1025
  11. Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: A prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41:1438–1444
  12. Zannad F, Kessler M, Lehert P, et al. Prevention of cardiovascular events in end-stage renal disease: Results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 2006;70:1318–1324
  13. Guerin AP, Blacher J, Pannier B, et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation. 2001;103:987–992
  14. Efrati S, Zaidenstein R, Dishy V, et al. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis. 2002;40:1023–1029
  15. Chow FY, Polkinghorne KR, Chadban SJ, et al. Cardiovascular risk in dialysis patients: A comparison of risk factors and cardioprotective therapy between 1996 and 2001. Nephrology (Carlton). 2003;8:177–183
  16. McCullough PA, Sandberg KR, Yee J, et al. Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease. J Renin Angiotensin Aldosterone Syst. 2002;3:188–191
  17. Winkelmayer WC, Charytan DM, Levin R, et al. Poor short-term survival and low use of cardiovascular medications in elderly dialysis patients after acute myocardial infarction. Am J Kidney Dis. 2006;47:301–308
  18. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003;42:201–208
  19. Tepel M, Giet MV, Park A, et al. Association of calcium channel blockers and mortality in haemodialysis patients. Clin Sci (Lond). 2002;103:511–515
  20. Boger CA, Gotz AK, Kruger B, et al. Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients. Eur J Med Res. 2005;10:161–168
  21. Avorn J. In defense of pharmacoepidemiology—Embracing the yin and yang of drug research. N Engl J Med. 2007;357:2219–2221
  22. Ray JG. Evidence in upheaval: Incorporating observational data into clinical practice. Arch Intern Med. 2002;162:249–254
  23. Ray WA. Evaluating medication effects outside of clinical trials: New-user designs. Am J Epidemiol. 2003;158:915–920
  24. Horwitz RI, Viscoli CM, Clemens JD, et al. Developing improved observational methods for evaluating therapeutic effectiveness. Am J Med. 1990;89:630–638
  25. Schneeweiss S, Patrick AR, Sturmer T, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care. 2007;45(suppl 2):S131–S142

 Originally published online as doi:10.1053/j.ajkd.2008.07.037 on November 20, 2008.

PII: S0272-6386(08)01238-9

doi: 10.1053/j.ajkd.2008.07.037

American Journal of Kidney Diseases
Volume 53, Issue 3 , Pages 457-466 , March 2009

Article Tools